Concentra Group Holdings Parent (CON) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
30 Jun, 2026Strategic rationale and industry context
Acquisition of Pivot Onsite Innovations accelerates growth and doubles the onsite health clinic segment size.
Onsite healthcare is a multi-billion dollar industry with strong secular tailwinds and significant whitespace for expansion.
Combined entity becomes the largest occupational health-focused onsite clinic provider in the U.S.
Enhanced ability to deliver occupational health and advanced primary care to large employers nationwide.
Synergy and cross-sell opportunities expected from complementary service offerings and expanded footprint.
Transaction details and financial impact
Purchase price of $55 million, funded with cash on hand and available liquidity.
Transaction expected to close in Q2 2025, subject to customary conditions.
Deal is immediately accretive to earnings, with a projected EBITDA multiple below 9x by year 2 post-synergy.
No material impact on net leverage ratio, maintaining targets of ~3.5x by year-end 2025 and ~3.0x in 18-24 months.
Integration will follow a proven playbook, focusing on capital-light and turnkey processes.
Market opportunity and operational scale
U.S. employer healthcare spending is approximately $1.3 trillion, with a $17 billion+ serviceable addressable market for onsite healthcare.
Over 30% of large employers have onsite or near-site clinics, with 40%+ reporting ROI of 1.5:1 or higher.
Combined onsite clinic footprint expands to about 357 locations across 43 states.
Workforce grows to over 1,200 colleagues, enhancing service delivery and expertise.
Concentra's onsite health clinics segment is positioned for long-term growth and increased market share.
Latest events from Concentra Group Holdings Parent
- Industry leader with $2.16bn revenue, strong margins, and robust growth across diversified channels.CON
Investor presentation30 Jun 2026 - Strong 2025 growth, high satisfaction, and disciplined expansion drive robust outlook.CON
44th Annual J.P. Morgan Healthcare Conference29 May 2026 - Q1 2026 saw 13.7% revenue growth, margin gains, and raised full-year guidance.CON
Q1 20268 May 2026 - Director elections, executive pay, and auditor ratification headline a governance-focused proxy.CON
Proxy Filing17 Mar 2026 - Director elections, executive pay, and auditor ratification headline the 2026 proxy.CON
Proxy Filing17 Mar 2026 - 2025 saw strong growth and margin gains; 2026 outlook projects continued robust performance.CON
Q4 202527 Feb 2026 - Q2 2024 revenue up 2.3% to $477.9M; IPO completed, supporting growth and deleveraging.CON
Q2 20242 Feb 2026 - Q3 revenue up 3.3% YoY, IPO completed, and 2024 guidance set at $1.9B revenue.CON
Q3 202417 Jan 2026 - 2025 guidance targets $2.1B revenue and double-digit growth from Nova integration.CON
Guidance9 Jan 2026